• Aktis Oncology released first-in-human imaging and dosimetry findings for its B7-H3-targeted radioconjugate AKY-2519, with data scheduled for presentation at the 2026 ASCO Annual Meeting on May 30.
• The readout showed strong tumor uptake with limited exposure in normal tissues across assessments in metastatic castration-resistant prostate cancer and a broader set of advanced solid tumors.
• The profile supported continued clinical development, including an ongoing Phase 1b study in mCRPC that includes PLUVICTO-naïve and PLUVICTO-experienced patients, with preliminary data expected in 2027.
• A second Phase 1b study in other B7-H3-expressing solid tumors is planned to start in the second half of 2026, expanding the program beyond prostate cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aktis Oncology Inc. published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.